Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC), a type of liver cancer, remains a treatment challenge due to late detection and resistance to currently approved drugs. It takes 15–20 years for a single new drug to become FDA approved. The purpose of this study was to expedite identification of novel...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Regan-Fendt, Kelly, Li, Ding, Reyes, Ryan, Yu, Lianbo, Wani, Nissar A., Hu, Peng, Jacob, Samson T., Ghoshal, Kalpana, Payne, Philip R.O., Motiwala, Tasneem
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7598246/
https://ncbi.nlm.nih.gov/pubmed/32977582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12102730
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars